Q2 26 EPS
$-0.21
BEAT +24.22%
Est. $-0.28
Q2 26 Revenue
$1.0M
MISS 90.52%
Est. $11.0M
Did ALEC Beat Earnings? Q2 2026 Results
Alector delivered a mixed first quarter for fiscal 2026, narrowing its loss more sharply than Wall Street expected even as collaboration revenue collapsed well below estimates. The neuroscience biotech posted an adjusted loss of $0.21 per share, beat… Read more Alector delivered a mixed first quarter for fiscal 2026, narrowing its loss more sharply than Wall Street expected even as collaboration revenue collapsed well below estimates. The neuroscience biotech posted an adjusted loss of $0.21 per share, beating the $0.28 consensus by 24.22%, extending its run of topping EPS expectations to four consecutive quarters. Revenue, however, came in at just $1.05 million against an $11.03 million estimate, a 90.52% miss and a 71.5% decline from the $3.67 million recorded a year ago, as manufacturing activity supporting the nivisnebart progranulin program dried up following the discontinuation of the PROGRESS-AD Phase 2 trial after an interim futility analysis. The bottom-line improvement was driven by steep cost cuts, with R&D expenses falling to $17.86 million from $33.64 million and G&A dropping to $8.11 million from $14.73 million, narrowing the net loss to $22.93 million. With $206.51 million in cash expected to fund operations through at least 2027, Alector is now pivoting fully toward its Alector Brain Carrier platform, targeting an IND submission for AL037/AL137 in Q1 2027.
Key Takeaways
- • Significant reduction in operating expenses driven by reductions in force and decreased AL002 program spending
- • Lower collaboration revenue due to decreased manufacturing-related activity supporting the nivisnebart Phase 2 study
ALEC Forward Guidance & Outlook
Management anticipates that cash, cash equivalents, and investments of $206.5 million as of March 31, 2026, will be sufficient to fund operations at least through 2027. The company is targeting an IND submission for AL037/AL137 in Q1 2027 and is advancing AL050 and AL164 through preclinical development. The strategic focus remains on the ABC platform across multiple therapeutic modalities.
ALEC YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
“Over the past seven years, we have built a highly differentiated blood-brain barrier platform with the versatility to deliver antibodies, enzymes, proteins, and siRNA to the brain. We have a rich and growing pipeline of ABC-enabled programs, and we remain deeply committed to developing therapies that can make a meaningful difference for patients living with neurodegenerative diseases.”
— Arnon Rosenthal, Q2 2026 Earnings Press Release
ALEC Earnings Trends
ALEC vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ALEC EPS Trend
Earnings per share: estimate vs actual
ALEC Revenue Trend
Quarterly revenue: estimate vs actual
ALEC Quarterly Results
7 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.28 | $-0.21 | +24.22% | $1.0M | -90.52% |
| Q1 26 BEAT | $-0.28 | $-0.21 | +24.22% | $1.0M | -90.52% |
| Q4 25 BEAT FY | $-0.36 | $-0.34 | +6.41% | $6.2M | +218.63% |
| FY Full Year | $-1.38 | $-1.39 | -1.09% | $21.0M | +24.39% |
| Q3 25 BEAT | $-0.41 | $-0.34 | +17.66% | $3.3M | -6.52% |
| Q2 25 BEAT | $-0.47 | $-0.30 | +36.17% | $7.9M | +180.73% |
| Q1 25 BEAT | $-0.46 | $-0.41 | +10.87% | $3.7M | -13.55% |
| Q4 24 BEAT FY | $-0.54 | $-0.02 | +96.33% | $54.2M | +165.82% |
| FY Full Year | — | $-1.23 | — | $100.6M | — |